[Regulatory] 503A vs 503B in one paragraph, because everyone conflates them
503A vs 503B in one paragraph, because everyone conflates them — a position I have arrived at slowly and would like tested. Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently. Kept the label from every vial. When the shortage status changed, having…
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
a 503B has to register and report, so there is a paper trail to ask for
What is the beyond-use date and what is it based on?
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.